BACKGROUND: The antibody response to pneumococcal conjugate vaccines (PCVs) in infants is variable. Factors responsible for this variability have not been fully elucidated. The objective of this study was to investigate whether pneumococcal carriage around the time of the first dose of 7-valent PCV (PCV7) affects serotype-specific immunologic response. METHODS:Healthy 2-month old infants were randomized to receive 2 (at the ages of 4 and 6 months) or 3 (at the ages of 2, 4, and 6 months) PCV7 doses and a booster dose (at the age of 12 months). Nasopharyngeal or oropharyngeal specimens were obtained for culture shortly before the first PCV7 dose. Serotype-specific immunoglobulin (Ig) G levels were measured at ages 2, 7, and 13 months. RESULTS: Of 545 children studied, 332 received a booster dose. The most common serotypes carried around the time of the first PCV7 dose were 6B (n = 37), 19F (n = 22), and 23F (n = 14). In carriers before the first dose, the IgG response to the carried serotype after 2 or 3 doses was significantly lower than in noncarriers. In contrast, response to the noncarried serotypes was not affected. Although all children responded to the booster dose, the response to the originally carried serotype was generally lower. CONCLUSIONS: Serotype-specific hyporesponsiveness to PCV7 after pneumococcal carriage in infants is demonstrated for the first time. This phenomenon was common, lasted for at least several months, and was only partially overcome by the 12-month booster. TRIAL REGISTRATION: isrctn.org identifier: ISRCTN28445844.
RCT Entities:
BACKGROUND: The antibody response to pneumococcal conjugate vaccines (PCVs) in infants is variable. Factors responsible for this variability have not been fully elucidated. The objective of this study was to investigate whether pneumococcal carriage around the time of the first dose of 7-valent PCV (PCV7) affects serotype-specific immunologic response. METHODS: Healthy 2-month old infants were randomized to receive 2 (at the ages of 4 and 6 months) or 3 (at the ages of 2, 4, and 6 months) PCV7 doses and a booster dose (at the age of 12 months). Nasopharyngeal or oropharyngeal specimens were obtained for culture shortly before the first PCV7 dose. Serotype-specific immunoglobulin (Ig) G levels were measured at ages 2, 7, and 13 months. RESULTS: Of 545 children studied, 332 received a booster dose. The most common serotypes carried around the time of the first PCV7 dose were 6B (n = 37), 19F (n = 22), and 23F (n = 14). In carriers before the first dose, the IgG response to the carried serotype after 2 or 3 doses was significantly lower than in noncarriers. In contrast, response to the noncarried serotypes was not affected. Although all children responded to the booster dose, the response to the originally carried serotype was generally lower. CONCLUSIONS: Serotype-specific hyporesponsiveness to PCV7 after pneumococcal carriage in infants is demonstrated for the first time. This phenomenon was common, lasted for at least several months, and was only partially overcome by the 12-month booster. TRIAL REGISTRATION: isrctn.org identifier: ISRCTN28445844.
Authors: Paul V Licciardi; Fiona M Russell; Anne Balloch; Robert L Burton; Moon H Nahm; Gwendolyn Gilbert; Mimi L K Tang; Edward K Mulholland Journal: Vaccine Date: 2014-03-06 Impact factor: 3.641
Authors: Shabir A Madhi; Peter Adrian; Mark F Cotton; James A McIntyre; Patrick Jean-Philippe; Shawn Meadows; Sharon Nachman; Helena Käyhty; Keith P Klugman; Avye Violari Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: David J Dowling; Simon D van Haren; Annette Scheid; Ilana Bergelson; Dhohyung Kim; Christy J Mancuso; Willemina Foppen; Al Ozonoff; Lynn Fresh; Terese B Theriot; Andrew A Lackner; Raina N Fichorova; Dmitri Smirnov; John P Vasilakos; Joe M Beaurline; Mark A Tomai; Cecily C Midkiff; Xavier Alvarez; James L Blanchard; Margaret H Gilbert; Pyone Pyone Aye; Ofer Levy Journal: JCI Insight Date: 2017-03-23
Authors: Carlos G Grijalva; Marie R Griffin; Kathryn M Edwards; John V Williams; Ana I Gil; Héctor Verastegui; Stella M Hartinger; Jorge E Vidal; Keith P Klugman; Claudio F Lanata Journal: Int J Epidemiol Date: 2013-06-14 Impact factor: 7.196
Authors: Joseph A Lewnard; Noga Givon-Lavi; Amit Huppert; Melinda M Pettigrew; Gili Regev-Yochay; Ron Dagan; Daniel M Weinberger Journal: J Infect Dis Date: 2015-12-23 Impact factor: 5.226